PUBLISHER: Lucintel | PRODUCT CODE: 1386204
PUBLISHER: Lucintel | PRODUCT CODE: 1386204
The future of the global pediatric vaccine market looks promising with opportunities in the infectious disease, cancer, allergy, pneumococcal disease, influenza, measles, and mumps, and rubella (MMR) applications. The global pediatric vaccine market is expected to reach an estimated $30.8 billion by 2030 with a CAGR of 5.7% from 2024 to 2030. The major drivers for this market are rising awareness of the benefits of these vaccines among parents and medical professionals, growing demand for combination vaccines, and continous development of new and innovative pediatric vaccines.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global pediatric vaccine by vaccine type, technology, application, and region.
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pediatric vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pediatric vaccine companies profiled in this report include-
Lucintel forecasts that conjugate is expected to witness highest growth over the forecast period due to its significant usage in pneumococcal and meningococcal diseases to provide restraining power against these viruses.
North America is expected to witness highest growth over the forecast period due to existence of robust healthcare infrastructure, supportive government initiative for immunization programs, and growing of pediatric population in the region.
Market Size Estimates: Pediatric vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Pediatric vaccine market size by vaccine type, technology, application, and region in terms of value ($B).
Regional Analysis: Pediatric vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different vaccine types, technologies, applications, and regions for the pediatric vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pediatric vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Answer: The global pediatric vaccine market is expected to reach an estimated $30.8 billion by 2030.
Answer: The global pediatric vaccine market is expected to grow with a CAGR of 5.7% from 2024 to 2030.
Answer: The major drivers for this market are rising awareness of the benefits of these vaccines among parents and medical professionals, growing demand for combination vaccines, and continous development of new and innovative pediatric vaccines.
Answer: The future of the pediatric vaccine market looks promising with opportunities in the infectious disease, cancer, allergy, pneumococcal disease, influenza, measles, and mumps, and rubella (MMR) applications.
Answer: Some of the key pediatric vaccine companies are as follows:
Answer: Lucintel forecasts that conjugate is expected to witness highest growth over the forecast period due to its significant usage in pneumococcal and meningococcal diseases to provide restraining power against these viruses.
Answer: North America is expected to witness highest growth over the forecast period due to existence of robust healthcare infrastructure, supportive government initiative for immunization programs, and growing of pediatric population in the region.
Answer: Yes, Lucintel provides 10% customization without any additional cost.